Co-Authors
This is a "connection" page, showing publications co-authored by CATHERINE HEALY and HANA EL SAHLY.
Connection Strength
0.535
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
Score: 0.201
-
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 May 01; 7(5):e2412835.
Score: 0.060
-
Risk of COVID-19 after natural infection or vaccination. EBioMedicine. 2023 Oct; 96:104799.
Score: 0.058
-
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023 09; 29(9):2334-2346.
Score: 0.057
-
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
Score: 0.057
-
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 01 03; 6(1):e2251974.
Score: 0.055
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
Score: 0.048